Latest news with #Polymed
Fashion Value Chain
13-08-2025
- Business
- Fashion Value Chain
Solo-Dex and Polymedicure Partner to Bring Opioid-Free Acute Pain Management to India and Major Asian Markets
Solo-Dex, Inc., a U.S.-based medical device innovator, and Polymedicure Ltd. (Polymed), Indias leading manufacturer of high-quality medical devices, today announced a strategic manufacturing and supply partnership to bring Solo-Dexs patented, opioid-free regional anesthesia solutions to hospitals across India for the first time. Under this agreement, Polymed will manufacture Solo-Dexs flagship product, the Fascile Continuous Peripheral Nerve Block system, in accordance with Solo-Dexs strict quality standards, for distribution across India and key global markets. The product is already approved for clinical use in the United States and Europe and is now set to support Indias expanding Enhanced Recovery After Surgery (ERAS) programs and the growth of outpatient surgical care. 'This is a game-changer for pain management in India,' said Steven Eror, CEO of Solo-Dex. 'Polymeds scale, precision, and strong regulatory framework make them the ideal manufacturing partner. Together, well deliver a transformative technology that goes far beyond suppressing pain-it blocks acute pain completely.' First-of-its-kind in India: Faster, Safer, Non-Opioid Pain Control Solo-Dexs patented device installs in under two minutes and enables continuous, localized pain relief without opioids. Unlike conventional methods that may require IV sedation and can result in patient delirium, Solo-Dex minimizes systemic drug exposure, and eliminates the need for oral opioids thereby improving patient safety, reducing recovery time, and decreasing demand on hospital resources. The technology is designed to seamlessly integrate with ERAS protocols, helping hospitals manage post-operative pain more efficiently. As Indias healthcare system increasingly embraces day surgery and outpatient models, Solo-Dex offers a solution that enhances patient throughput and satisfaction without compromising clinical outcomes. 'We are excited to be part of this international collaboration,' said Himanshu Baid, Managing Director of Polymed. 'This partnership not only brings cutting-edge pain management to Indian clinicians and patients, but also aligns with our commitment to making world-class healthcare more accessible.' Designed for Global Impact Manufacturing will take place in Polymeds ISO 13485-certified, FDA-auditable facilities, with initial orders for 100,000 units. In addition to serving India, the partnership aims to fulfill international demand across Asia, Africa, Latin America, and select European markets, with Solo-Dex overseeing global regulatory compliance and branding. 'Thanks to this agreement, Solo-Dex now has the scalable, cost-effective production capacity to meet global demand while maintaining the clinical precision and quality our technology requires,' said Eror. 'Were especially proud to collaborate with Polymed to address the worldwide need for safer, opioid-free surgical recovery.' The Solo-Dex and Polymed partnership is already engaging with leading hospital systems across India, with commercial availability expected to begin in Q4 2025. About Solo-Dex, Inc. Solo-Dex is a U.S.-based medical device company focused on opioid-free acute pain management. Its patented continuous peripheral nerve block systems enable anesthesiologists to deliver localized, long-lasting anesthesia for post-surgical recovery. Solo-Dex technology is approved for clinical use in the U.S. and EU. About Polymedicure Limited Polymed is one of Indias most trusted names in medical devices, with a portfolio of more than 125 FDA-approved and CE-marked products. With a global presence in over 100 countries, Polymed operates high-end manufacturing facilities and is committed to delivering innovative, high-quality healthcare solutions at scale.
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
Medical device company share price zooms 47% in 1 month. Do you own?
Poly Medicure share price today: Shares of Poly Medicure, a leading medical device company with a dominant position in India's medical consumables market, rallied 5 per cent to ₹2,922 on the BSE in Wednesday's intra-day trade after it reported a healthy financial performance for the quarter ended March 2025 (Q4FY25). The stock price of the company is trading at its highest level in calendar year 2025. It had hit a 52-week high of ₹3,350 touched on November 1, 2024. In the past one month, the stock price of Poly Medicure has zoomed 47 per cent, as compared to 2.6 per cent rise in the BSE Sensex. At 10:31 am; Poly Medicure was trading 4 per cent higher at ₹2,884.90, as against 0.11 per cent decline in the benchmark index. Poly Medicure Q4 result Revenue from operations increased by 17 per cent to ₹440.80 crore in Q4FY25 over the previous year quarter. Export revenue growth was driven by continued strong performance in key international markets. Geopolitical tensions and tariff war has created short term demand uncertainty in certain export markets, the company said. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) grew by 24 per cent to ₹119.5 crore in Q4FY25 on a YoY basis, reflecting strong earnings capability from core operations. Ebitda margin has improved by 160 bps to 27 per cent in Q4FY25. Profit after tax increased by 34 per cent in Q4FY25. Management commentary The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. The management believes that the India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains. The company's investment in 3 new plants is going on strongly, which the management believes positions the company very strongly to achieve the significant growth opportunities. Crisil's view on Poly Medicure Continuous capacity addition and product innovation and development will support revenue growth over the medium term as well. Ebitda margin is expected to remain stable at 26-27 per cent over the medium term. The margin should be supported by better economies of scale, which in turn will be led by steady capacity utilisation, modernisation of facilities and cost-cutting initiatives. About Poly Medicure Poly Medicure is a leading medical device manufacturer and exporter from India, with its products sold in over 125 countries, making a significant global impact on healthcare. With a robust portfolio of over 200 medical devices and more than 300 patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management.
